YD Bio Limited

Advancing Diagnostics and Regenerative Health for a Healthier Tomorrow

[YD Bio Limited @YD_Bio_Limited]

Cross-continental patent coverage = multiple markets with real barriers to entry. Not just defensive — commercial assets that can be licensed, partnered, and monetized.

#YDBio #Patents #IP #PrecisionMedicine

[YD Bio Limited @YD_Bio_Limited]

Technology can be learned. Patents are much harder to get around.
YD Bio's IP portfolio has been quietly expanding 🧵

✨Pipeline → https://t.co/1WRtODnBXw

[YD Bio Limited @YD_Bio_Limited]

🔹 Cancer detection patents — licensed across the Americas, Europe & Asia-Pacific
🔹 Pancreatic cancer IP — U.S. granted
🔹 Colorectal cancer — key markets advancing
🔹 Ophthalmology platform — exclusive license

[YD Bio Limited @YD_Bio_Limited]

🎗️June is #NationalCancerSurvivorsMonth. Survival starts with early detection.

OkaiDx™ uses DNA methylation-based technology to find cancer before it advances. 💙

👉 Order now → https://t.co/TiVYvlM5tY

[YD Bio Limited @YD_Bio_Limited]

🌏 Market: Expansion planned for Maryland, Pennsylvania, Rhode Island & New Jersey. Taiwan & Hong Kong launch in progress. Up to 3 acquisitions in evaluation.

👉 Follow us for updates: https://t.co/WQiVSiK9Gr

#YDBio #Biotech #2026

[YD Bio Limited @YD_Bio_Limited]

n 2026, there are a few things worth watching at YD Bio.

Three platforms.
Multiple catalysts.
Here's the breakdown 🧵

👉 Full roadmap → https://t.co/1WRtODo9N4

[YD Bio Limited @YD_Bio_Limited]

👁️ Eye: Clinical trial launch in Taiwan + FDA IND submission + AMD preclinical complete
🔬 Cancer: OkaiDx™ data analysis done + Breakthrough Device submission + AACR data release

[YD Bio Limited @YD_Bio_Limited]

Three tracks running in parallel: research, clinical development, and consumer products. Stem cell therapy is closer than most people think.

Follow us for updates 👁️→ https://t.co/wYczqM7ikG

#YDBio #Exosome #StemCell

[YD Bio Limited @YD_Bio_Limited]

"Stem cell therapy = injecting cells into your eye." Not quite. YD Bio uses exosomes — tiny repair-signal packets naturally secreted by limbal stem cells.

Applied as eye drops. No live cell implantation needed 🧵

[YD Bio Limited @YD_Bio_Limited]

📍"Still lab-stage?"
No. Full FDA documentation filed. Clinical research launching in Taiwan in 2026.

📍"Regular people can't access it?"
Exovisse™ is already available in the U.S.

[YD Bio Limited @YD_Bio_Limited]

Not a grey area. Properly checked. Exovisse™ is now available nationwide across the U.S.

👉 Learn more → https://t.co/N2ef02TmbO

#YDBio #Exovisse #FDA #EyeHealth

[YD Bio Limited @YD_Bio_Limited]

When you pick up eye drops or put in contacts, how do you know they're safe?

There's actually a real FDA system behind that. A quick breakdown using YD Bio's Exovisse™ as the example 🧵

[YD Bio Limited @YD_Bio_Limited]

🔹 Contact Lenses: FDA 510(k) cleared — reviewed and confirmed safe before going on sale

🔹 Artificial Tears: meet FDA OTC standards, authorized for nationwide sales across the U.S.

[YD Bio Limited @YD_Bio_Limited]

What's next:
→ Dry eye clinical trial in Taiwan + IND submission to FDA, 2026
→ AMD exosome first-in-human trial, 2027

Follow us for updates 👁️
🔗 https://t.co/WQiVSiJBQT

[YD Bio Limited @YD_Bio_Limited]

👁️ Can the eye actually heal itself?
Dry eye, macular degeneration, corneal damage — conditions affecting hundreds of millions, with no real path to recovery. Until now.

YD Bio is changing that.
🔗 https://t.co/WQiVSiJBQT

[YD Bio Limited @YD_Bio_Limited]

In 2025, we delivered:
🔹 Exovisse™ Contact Lenses — FDA 510(k) cleared
🔹 Exovisse™ Artificial Tears — OTC-compliant, now available across the U.S.
🔹 LSC Exosomes — enrolled in the FDA Drug Master File

[YD Bio Limited @YD_Bio_Limited]

Next up: LSC exosome therapeutics for dry eye, glaucoma and corneal injury, with exosome-based lenses and artificial tears planned for clinical trials in 2027. 🌿

We'll share more as the work progresses.

[YD Bio Limited @YD_Bio_Limited]

👁️ Regenerative science is starting to make its way into everyday eye care.
YD Bio (Nasdaq: $YDES) has entered the U.S. ophthalmology market with partner 3D Global Biotech. 🧬
👉 https://t.co/LgQlmgaqwx

[YD Bio Limited @YD_Bio_Limited]

Two products are already cleared:
✅ Exovisse™ Contact Lenses — FDA 510(k) (Class II)
✅ Exovisse™ Artificial Tears — FDA OTC Monograph M018, sold nationwide
Both available now to help with dry eyes. 💧

[YD Bio Limited @YD_Bio_Limited]

🌍 Leading institutions worldwide are converging on dendritic cell immunotherapy for GBM.

🇧🇷 São Paulo — Phase III registered
🇳🇴 Oslo — Phase II/III recruiting
🇹🇼 SSMC — Phase III underway in Taiwan

This is why YD Bio is advancing its acquisition of SSMC. 🩶